ArciTect Hu CRISPR Optimization Kit, FI

Designed by STEMCELL Technologies for the optimization of genome editing workflows in human cells, this kit from the ArciTect™ product line enables rapid, quantitative assessment of editing efficiency by flow cytometry. It can also be used as a positive control for experiments using the ArciTect™ CRISPR-Cas9 genome editing system in human cells.

The kit comprises three components: ArciTect™ Human B2M sgRNA, ArciTect™ Cas9 Nuclease, and a fluorophore-conjugated anti–beta-2 microglobulin (B2M) antibody. The Cas9 Nuclease is first complexed with the B2M sgRNA, delivered into human cells, and cultured for 48–96 hours. Editing efficiency is then assessed by flow cytometry using the fluorophore-conjugated B2M antibody. Because B2M encodes a ubiquitously expressed cell-surface protein, loss of B2M expression provides a clear readout of editing success, while also enabling additional evaluation such as viability monitoring and assessment of cell type-specific marker expression.

This FITC-conjugated variant includes the Anti-Human Beta-2 Microglobulin Antibody, Clone 35, a monoclonal mouse IgG1 antibody raised against recombinant human B2M. The antibody is provided at 0.1 mg/mL in an aqueous solution containing 0.5% bovine serum albumin (BSA) and 0.03% ProClin™ 300, and is validated for flow cytometry applications on human cells. The kit has been tested and validated for use with the ArciTect™ line of genome editing products and has demonstrated editing in human pluripotent stem cells, T cells, and CD34+ hematopoietic stem and progenitor cells.